→
Investors should consider the significant fluctuations in Hims & Hers' stock price and the implications of regulatory developments on its business model.
Hims & Hers Health, Inc. has a market capitalization of approximately $6.45B and a current price of $24.99, reflecting a significant decline of 14.8% from the previous close of $29.33. The company reported a year-over-year revenue growth of 59%, although its EPS growth is down by 3.77%. Key metrics include a P/E ratio of 49.00 and a P/S ratio of 2.75, with a 52-week high of $70 and a low of $13.75.
Some investors may point to Hims & Hers' impressive revenue growth of 59% year-over-year as a strong indicator of demand for its services. Additionally, the company's return on equity (ROE) stands at 23.73%, which suggests effective management of shareholder equity.
Concerns have been raised following the FTC's lawsuit alleging that Hims & Hers shared health data improperly, which could undermine consumer trust. Furthermore, the stock's decline of 14.8% in one day highlights potential volatility and investor reaction to regulatory risks.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start. Pro unlocks the full terminal at $20/mo.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Hims & Hers Health, Inc. has a market capitalization of approximately $6.45B and a current price of $24.99, reflecting a significant decline of 14.8% from the previous close of $29.33. The company reported a year-over-year revenue growth of 59%, although its EPS growth is down by 3.77%. Key metrics include a P/E ratio of 49.00 and a P/S ratio of 2.75, with a 52-week high of $70 and a low of $13.75.
Concerns have been raised following the FTC's lawsuit alleging that Hims & Hers shared health data improperly, which could undermine consumer trust. Furthermore, the stock's decline of 14.8% in one day highlights potential volatility and investor reaction to regulatory risks.
Some investors may point to Hims & Hers' impressive revenue growth of 59% year-over-year as a strong indicator of demand for its services. Additionally, the company's return on equity (ROE) stands at 23.73%, which suggests effective management of shareholder equity.
Some investors may point to Hims & Hers' impressive revenue growth of 59% year-over-year as a strong indicator of demand for its services. Additionally, the company's return on equity (ROE) stands at 23.73%, which suggests effective management of shareholder equity. Concerns have been raised following the FTC's lawsuit alleging that Hims & Hers shared health data improperly, which could undermine consumer trust. Furthermore, the stock's decline of 14.8% in one day highlights potential volatility and investor reaction to regulatory risks.
Hims & Hers Health, Inc. has a market capitalization of approximately $6.45B and a current price of $24.99, reflecting a significant decline of 14.8% from the previous close of $29.33. The company reported a year-over-year revenue growth of 59%, although its EPS growth is down by 3.77%. Key metrics include a P/E ratio of 49.00 and a P/S ratio of 2.75, with a 52-week high of $70 and a low of $13.75.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for HIMS at helmterminal.dev/analyze/HIMS, updated continuously during US market hours. No signup required.